Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity? Laiba Immad Tue, June 30, 2026 at 8:08 PM GMT+7 2 min read XERS We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list.

The Fly reported on June 11 that XERS announced that the USPTO issued a notice of allowance for U.S. Patent Application No. 17/151,405, covering compositions and methods of use related to its Keveyis product. The allowed claims were determined to meet patentability requirements and are expected to advance toward patent issuance after completing standard administrative procedures. Following approval, Xeris plans to submit the patent for inclusion in the FDA's Orange Book listing. If issued and maintained through required filings and fees, the new patent is expected to extend intellectual property protection for Keveyis through 2039.

Simultaneously, on June 11, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) entered into privately negotiated exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Under the agreements, the company plans to retire approximately $23 million in principal amount of notes through a combination of cash payments and common stock issuance. The number of shares issued will depend on the volume-weighted average trading price of XERS common stock during a 21-day averaging period beginning June 11. Based on an assumed average price of $6.71, XERS expects to issue about 4.6 million shares. After completion, approximately $10.5 million of notes will remain outstanding.